OPHLF News and Press, Ono Pharmaceutical Co Ltd From 08/31/23

2023-08-31 06:45:33 ET More on Twist Twist Bioscience: Progress Hidden By Execution Issues And Soft Demand Twist Bioscience: Evaluating Its Conglomerate Of Innovation, Growth, And Vulnerabilities Twist Bioscience Corporation ( TWST ) Q3 2023 Earnings Call Trans...

2023-08-16 09:05:49 ET Summary Fate Therapeutics is a cell therapy company focused on CAR-T and NK cells for autoimmune diseases and cancer. Their product candidates are still in early clinical trials or preclinical stages, making their path forward uncertain. The company has ...

2023-05-11 10:29:16 ET Ono Pharmaceutical press release ( OTCPK:OPHLF ): FY GAAP EPS of ¥230.79. Revenue of ¥447.18B (+23.7% Y/Y). For further details see: Ono Pharmaceutical GAAP EPS of ¥230.79, revenue of ¥447.18B

Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...

Ono Pharmaceutical press release ( OTCPK:OPHLF ): Q2 GAAP EPS of ¥127.66. Revenue of ¥216.7B (+24.5% Y/Y). For further details see: Ono Pharmaceutical GAAP EPS of ¥127.66, revenue of ¥216.7B

Ono Pharmaceutical press release ( OTCPK:OPHLF ): Q1 GAAP EPS of ¥60.36. Revenue of ¥106.72B (+22.2% Y/Y). For further details see: Ono Pharmaceutical GAAP EPS of ¥60.36, revenue of ¥106.72B

The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February

eFFECTOR Therapeutics is a biopharmaceutical company focused on development of selective translation regulation inhibitors (STRIs) for treating cancer. CEO Dr. Steve Worland discusses its 2 drugs in clinical trials and collaboration with Pfizer. Going public in Q3 2021 through SPA...

The following slide deck was published by Ono Pharmaceutical Co., Ltd. in conjunction with their 2022 Q1 earnings call. For further details see: Ono Pharmaceutical Co., Ltd. 2022 Q1 - Results - Earnings Call Presentation

Ono Pharmaceutical (OTC:OPHLF): Q1 GAAP EPS of ¥48.22. Revenue of ¥87.36B (+16.6% Y/Y). Press Release For further details see: Ono Pharmaceutical reports Q1 results